subscribeSubscribe
MEI and Kyowa Kirin to discontinue development of zandelisib outside Japan

MEI and Kyowa Kirin to discontinue development of zandelisib outside Japan
PHARMACEUTICAL-TECHNOLOGY
07 Dec 2022
Share Share
MEI Pharma & Kyowa Kirin Announce Discontinuation of Zandelisib Outside of Japan

MEI Pharma & Kyowa Kirin Announce Discontinuation of Zandelisib Outside of Japan
BUSINESSWIRE
06 Dec 2022
Share Share
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BUSINESSWIRE
01 Aug 2022
Share Share
MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology

MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology
BUSINESSWIRE
18 Jul 2022
Share Share
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at ASCO 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at ASCO 2022
BUSINESSWIRE
04 Jun 2022
Share Share
FDA rebuffs MEI, Kyowa Kirin as another cancer drug class draws scrutiny

FDA rebuffs MEI, Kyowa Kirin as another cancer drug class draws scrutiny
Jonathan Gardner BIOPHARMADIVE
26 Mar 2022
Share Share
MEI Pharma, Kyowa Kirin Provide Regulatory Update on Zandelisib

MEI Pharma, Kyowa Kirin Provide Regulatory Update on Zandelisib
BUSINESSWIRE
24 Mar 2022
Share Share
Mei, with Bayer and Gilead in its sights, posts pivotal data

Mei, with Bayer and Gilead in its sights, posts pivotal data
Nick Paul Taylor FIERCEBIOTECH
30 Nov 2021
Share Share
MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL

MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL
BUSINESSWIRE
29 Nov 2021
Share Share
MEI Pharma and Kyowa Kirin receive Orphan Drug Designation for Zandelisib

MEI Pharma and Kyowa Kirin receive Orphan Drug Designation for Zandelisib
BUSINESSWIRE
10 Nov 2021
Share Share